New Pharmacoeconomic Study Shows Avonex® Is Cost-Effective For Multiple Sclerosis Therapy
Cambridge, MA - Biogen Idec Inc. (NASDAQ: BIIB) announced that one-year data presented at the Academy of Managed Care Pharmacy’s (AMCP) 2007 Annual Meeting show that AVONEX® is a cost-effective therapy in multiple sclerosis (MS) when compared to other interferon beta treatments.
Using a comprehensive analysis of medical and pharmacy costs, the results of the research concluded that patients treated with AVONEX, the most prescribed MS therapy worldwide, have the lowest total one-year cost to a health plan when compared to other interferon beta treatments.
Researchers analyzed 10,622 patients over one year to assess how demographic, administrative and clinical variables affect MS costs and utilization patterns and to examine the economic impact of treating MS. The independent data contained in Multiple Sclerosis Benchmarksä , the retrospective, claims-based, observational study, showed that patients treated with AVONEX had the lowest average one-year cost compared to patients receiving other interferon beta treatments. It has been estimated that the total annual economic burden of MS in the United States exceeds $6.8 billion with a lifetime cost of $2.2 million per patient.
“MS is a disease that can have an impact beyond its debilitating effect on patients,” said Michael Pollock, Vice President, Global Health Economics, Biogen Idec. “Cost-effectiveness is an increasingly important factor in treating chronic diseases like MS. This study shows that in addition to its clinical impact, AVONEX can also help to substantially reduce the cost of care for patients living with this disease, when compared to other interferon beta treatments.”
The MS Benchmarks analysis showed the total costs over one-year to MS patients on interferon beta therapy were: AVONEX, $19,896.15; Rebif® (Interferon beta-1a) sc, $22,207.85; and Betaseron® (Interferon beta-1b), $21,073.33.
In addition, AVONEX patients were more likely to refill their prescriptions (avg.9.6/yr vs. 8.1 and 8.2/yr for other interferon beta therapies) and were less likely to use certain concomitant medications. Over the one-year period, use of disease-modifying therapies (interferon beta and glatiramer acetate) was almost always observed as monotherapy, reflecting little evidence of combination use or switching between products.
Additionally, according to data from the Quality Assessment of Multiple Sclerosis Therapy (QUASIMS) study presented at the AMCP Conference, patients do not derive additional clinical benefit from switching among interferon beta therapies. QUASIMS, an open-label, retrospective, observational study conducted in 14 countries, analyzed 7,156 MS patients who had received two years of uninterrupted therapy with interferon beta as initial therapy or follow-up therapy.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.